Last updated on August 2019

Cognite Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease


Brief description of study

Cognite Trial – A Phase III Safety and Efficacy Study of ALZT-OP1 in Individuals with Evidence of Early Alzheimer’s Disease

Detailed Study Description

This Phase III study is designed as a randomized, double-blinded, placebo-controlled study for subjects with evidence of early AD. The study will evaluate safety and tolerability, efficacy as measured by CDR-SB, and will determine if the combination therapy ALZT-OP1 will slow down, arrests, or reverse cognitive and functional decline in an early stage AD population.

Clinical Study Identifier: TX143284

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.